Methylated NEUROD1 promoter is a marker for chemosensitivity in breast cancer

Heidi Fiegl, Allison Jones, Cornelia Hauser-Kronberger, Georg Hutarew, Roland Reitsamer, Robin L. Jones, Mitch Dowsett, Elisabeth Mueller-Holzner, Gudrun Windbichler, Günter Daxenbichler, Georg Goebel, Christian Ensinger, Ian Jacobs, Martin Widschwendter

    Research output: Contribution to journalArticlepeer-review

    Abstract

    Purpose: Chemotherapy can be an integral component of the adjuvant management strategy for women with early stage breast cancer. To date, no tool is available to predict or monitor the efficacy of these therapies. The aim of this proof-of-principle study was to assess whether NEUROD1 DNA methylation is able to predict the response to neoadjuvant and adjuvant chemotherapy. Experimental Design: Recently, we showed that NEUROD1 DNA is differentially methylated in neoplastic versus nonneoplastic breast tissue samples. In this study, we used MethyLight and analyzed NEUROD1 methylation in (a) 74 breast cancer tissue samples, (b) two independent sets of pretreatment core biopsies of 23 (training set) and 21 (test set) neoadjuvantly treated breast cancer patients, and (c) pretherapeutic and posttherapeutic serum samples from 107 breast cancer patients treated with adjuvant chemotherapy. Results: High-grade tumors showed higher NEUROD1 methylation levels. Estrogen receptor-negative breast cancers with high NEUROD1 methylation were 10.8-fold more likely to respond with a complete pathologic response following neoadjuvant chemotherapy. Patients with positive serum pretreatment NEUROD1 methylation, which persisted after chemotherapy, indicated poor relapse-free and overall survival in univariate and multivariate analyses (relative risk for relapse, 6.2; 95% confidence interval, 1.6-24; P = 0.008, and relative risk for death, 14; 95% confidence interval, 1.6-120; P = 0.02). Conclusions: These data support the view that NEUROD1 methylation is a chemosensitivity marker in estrogen receptor - negative breast cancer. © 2008 American Association for Cancer Research.
    Original languageEnglish
    Pages (from-to)3494-3502
    Number of pages8
    JournalClinical Cancer Research
    Volume14
    Issue number11
    DOIs
    Publication statusPublished - 1 Jun 2008

    Fingerprint

    Dive into the research topics of 'Methylated NEUROD1 promoter is a marker for chemosensitivity in breast cancer'. Together they form a unique fingerprint.

    Cite this